Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor … – PR Newswire (press release)
|
Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor …
PR Newswire (press release) In a study presented today at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, the world’s premier oncology event, researchers at Poseida used its proprietary gene editing tools to create a universal donor CAR–T cell therapy that … |
|
Chinese cell therapy effective in small multiple myeloma trial
Reuters The study of 35 patients tested a chimeric antigen receptor T–cell (CAR-T) therapy developed by China’s Nanjing Legend Biotech Co. The drug candidate, known as LCAR-B38M, targets a protein called BCMA found on cancerous blood plasma cells – the … |
|
Bluebird is pretty chirpy about its anti-BCMA CAR–T therapy results
MedCity News You know you’re on to something worthwhile when your study leader can’t quite hold back the tears when presented with the final data. That was the case with Bluebird Bio’s first major clinical trial for its experimental anti-BCMA CAR–T cell therapy in … |
|
ACEA Biosciences Announces Collaboration with Memorial Sloan Kettering Cancer Center on Personalized CAR T …
Business Wire (press release) ACEA’s xCELLigence RTCA instrument can monitor this cancer cell killing process in real-time without the use of labels so it provides a means of assessing CAR T cell potency under conditions that are of maximal physiological relevance. Dr. Prasad S. |
Lab News |
Breakthrough means patient specific stem cells
Lab News Scientists in the US have created blood-forming stem cells from patients’ own cells, moving a step closer to being able to produce all types of blood cells to treat disease. The cells that were produced from the pluripotent stem cells were a mixture of … |